{"id":"cg53135-05-velafermin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108059","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by promoting the formation of new blood vessels and enhancing the healing process in various tissues. This is achieved through its interaction with FGF receptors, which triggers a cascade of signaling events leading to increased angiogenesis and tissue repair.","oneSentence":"Velafermin is a recombinant human fibroblast growth factor 2 (FGF-2) that stimulates angiogenesis and wound healing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:25:48.827Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic foot ulcers"},{"name":"Venous leg ulcers"}]},"trialDetails":[{"nctId":"NCT00323518","phase":"PHASE2","title":"A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis","status":"COMPLETED","sponsor":"CuraGen Corporation","startDate":"2006-05","conditions":"Oral Mucositis, Stomatitis","enrollment":390},{"nctId":"NCT00104065","phase":"PHASE2","title":"Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant","status":"COMPLETED","sponsor":"CuraGen Corporation","startDate":"2005-01","conditions":"Stomatitis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CG53135-05, velafermin","genericName":"CG53135-05, velafermin","companyName":"CuraGen Corporation","companyId":"curagen-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Velafermin is a recombinant human fibroblast growth factor 2 (FGF-2) that stimulates angiogenesis and wound healing. Used for Diabetic foot ulcers, Venous leg ulcers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}